Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET) : an international, open-label, randomised, phase 3 trial

  • Christopher J. Sweeney
  • , Andrew J. Martin
  • , Martin R. Stockler
  • , Stephen Begbie
  • , Leanna Cheung
  • , Kim N. Chi
  • , Simon Chowdhury
  • , Mark Frydenberg
  • , Lisa G. Horvath
  • , Anthony M. Joshua
  • , Nicola J. Lawrence
  • , Gavin Marx
  • , John McCaffrey
  • , Ray McDermott
  • , Margaret McJannett
  • , Scott A. North
  • , Francis Parnis
  • , Wendy Parulekar
  • , David W. Pook
  • , Martin Neil Reaume
    • Shahneen K. Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott G. Williams, Diana Winter, Sonia Yip, Alison Y. Zhang, Robert R. Zielinski, Ian D. Davis, ENZAMET trial investigators, Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Research output: Contribution to journal › Article › peer-review

164 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET) : an international, open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science